Tele: 561.316.3330
Breaking Medical Device News

Tuesday, September 21, 2021

MEDICAL DEVICE NEWS MAGAZINE

A DIGITAL PUBLICATION FOR THE PRACTICING MEDICAL SPECIALIST, INDUSTRY EXECUTIVE AND INVESTOR
HomeIndivumed GmbHIndivumed Partners with Oslo University Hospital to Advance Cancer Research

Indivumed Partners with Oslo University Hospital to Advance Cancer Research

Indivumed GmbH (“Indivumed”) today announced a joint research collaboration to expand IndivuType by adding digital pathology images and data using cutting-edge technology from the Institute for Cancer Genetics and Informatics (“ICGI”) at Oslo University Hospital, a world leader in the application of Deep Learning and AI in oncology.

By scanning high-resolution images of haematoxylin and eosin-stained tumor section slides for all IndivuType cases, Indivumed will be able to leverage an entirely new dimension of data in the coming months. The expansion of IndivuType’s digital pathology asset and analysis capacity will allow Indivumed and ICGI to combine the cancer phenotype, as defined by the tumor morphology, with the deep molecular multi-omics characterization of the tumor, resulting in better prognostic and diagnostic algorithms which will aid in the personalized treatment of cancer. Furthermore, the project will use the multi-omics data to unlock the black box of Deep Learning to create completely novel insights into tumor biology.

“We are constantly driven by our mission to unveil the complex mechanisms of cancer in order to advance precision oncology,” said Roald Forsberg, PhD, Indivumed Chief Business Officer and Head of the IndivuType Business Unit. “Our collaboration with the renowned ICGI team at Oslo University Hospital is truly unique in that it will result in the creation of the world’s first data asset to combine full multi-omics data with clinical and digital pathology data.”

Indivumed will work closely with the Institute for Cancer Genetics and Informatics (ICGI) at Oslo University Hospital to leverage artificial intelligence algorithms to deliver a fully automated method of prognosis for colorectal cancer. IndivuType will utilize the analytical data generated from the standardized global collection of thousands of high-quality patient samples to validate the prognosis method and identify multi-omic signatures that can explain the underlying biology behind the algorithm. The resulting discoveries will be used to explore new avenues of cancer treatment and prevention.

“The success of our program relies on a unique combination of academic and industrial competence using artificial intelligence and digital tools in pathology,” said Professor Håvard E. Danielsen, Director of the Institute for Cancer Genetics and Informatics (ICGI) at Oslo University Hospital. “Working with Indivumed and the tremendous amount of high-quality data contained within the IndivuType discovery solution will help us to better understand the underlying biology of colorectal cancer and more accurately identify potential biomarkers and therapeutic targets.”

Indivumed and the Institute for Cancer Genetics and Informatics at Oslo University Hospital expect to publish several papers detailing the outcomes of the collaboration and explore commercial opportunities based on the refinement of prognostic algorithms and the discovery of novel insights into the molecular drivers of cancer morphology and biology.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

FDA Authorizes Software that Can Help Identify Prostate Cancer

The software is called Paige Prostate and is compatible for use with slide images that have been digitized using a scanner.

Shannon Lantzy MedCrypt New VP of Consulting

"I met Shannon at a healthcare-related event several years ago and was immediately impressed with her passion and drive to move healthcare into a digital future," said Mike Kijewski, CEO of MedCrypt.

Mark Foster Joins Xenocor BOD

Foster is a versatile and visionary C-Suite executive who brings 20 years of general management and leadership experience from both venture-backed growth-stage organizations and world-class medical device companies

Hinge Health Acquires the Most Advanced Computer Vision Technology for Tracking Human Motion

CEO Daniel Perez explained, “We won’t stop investing in technology to deliver the most patient-centered digital clinic that improves member experience and outcomes while reducing costs. wrnch allows us to take a giant leap forward in all respects.”

Dale W Wood Congratulates the Huma Team on Raising $130 Million

Major health and technology companies across the world have committed upwards of $130 million to Huma Therapeutics, the health-tech company backed by Dale Ventures.

Rhaeos Awarded $4 Million NIH SBIR Grant

Under the NIH SBIR grant, Rhaeos will leverage their existing wireless sensor hardware to provide additional quantitative flow data to the clinician, giving insight into this currently inaccessible and highly relevant shunt performance metric.

Gynesonics Announces FDA Clearance of Next Generation Sonata System

“This clearance brings significant system improvements that expand the location of fibroids that can be treated while allowing the physician to control all aspects of the treatment from within the sterile field,” said Jiayu Chen, Ph.D. Vice President, Engineering and Advanced Technologies at Gynesonics.

Blackrock Neurotech Invests In Groundbreaking Auditory Nerve Implant With University Of Minnesota And MED-EL

The new investment will enable the development and translation of a new ANI through preclinical studies and later, a pilot clinical trial, where the ANI is then implanted in up to three deaf patients.

By using this website you agree to accept Medical Device News Magazine Privacy Policy